GLP-1 Drug Exenatide Outperforms Empagliflozin and Quercetin for Diabetes in Rats, But Triple Combo Works Best
Exenatide was the most effective single-drug treatment for type 2 diabetes in rats, but combining it with empagliflozin and quercetin produced the best overall improvements in blood sugar, insulin resistance, and cholesterol.
Quick Facts
What This Study Found
In type 2 diabetic rats, the GLP-1 agonist exenatide showed more pronounced antidiabetic effects than either empagliflozin (an SGLT2 inhibitor) or quercetin (a plant flavonoid) when used alone. However, the triple combination of all three drugs produced the best overall results.
All treatments lowered glucose, HbA1c, and triglyceride levels. Exenatide and the combination therapy were the only treatments to increase insulin levels. The combination was uniquely effective at decreasing leptin levels and HOMA-IR (insulin resistance). Exenatide improved HDL cholesterol and LDL levels, while the combination therapy showed the strongest combined antidiabetic and lipid-lowering effects.
Key Numbers
n=67 rats · 7 groups · exenatide 10 μg/kg · empagliflozin 50 mg/kg · quercetin 50 mg/kg · 8-week treatment · all treatments ↓ glucose and HbA1c · combination uniquely ↓ HOMA-IR and leptin · exenatide ↑ HDL
How They Did This
67 Wistar Albino male rats were divided into seven groups: healthy control, diabetes control, diabetes + sham, and four treatment groups (exenatide, empagliflozin, quercetin, and triple combination). Diabetes was induced and treatments were administered for 8 weeks. Outcomes measured included blood glucose, HbA1c, insulin, adiponectin, leptin, total antioxidant levels, LDL, HDL, triglycerides, HOMA-IR (insulin resistance), and HOMA-β (beta cell function).
Why This Research Matters
Type 2 diabetes management often requires multiple drugs with complementary mechanisms. This study systematically compared a peptide drug (exenatide), a newer oral drug (empagliflozin), and a natural compound (quercetin) both alone and in combination. The finding that exenatide outperformed the others as monotherapy reinforces GLP-1 agonists' strong position in diabetes treatment. The superior results from triple combination therapy suggest that adding quercetin as a supplement alongside prescription medications could enhance metabolic outcomes.
The Bigger Picture
Combination therapy is becoming the standard of care for type 2 diabetes, and this study supports that trend at the preclinical level. The inclusion of quercetin — a naturally occurring flavonoid found in onions, apples, and berries — alongside two prescription drugs is noteworthy because it suggests that dietary supplements could meaningfully complement pharmaceutical therapy. As GLP-1 agonists become increasingly dominant in diabetes and obesity management, understanding how they synergize with other drug classes remains an active research priority.
What This Study Doesn't Tell Us
This is an animal study in rats with chemically induced diabetes, which may not fully replicate human type 2 diabetes. The drug doses were selected for rats and may not translate directly to human dosing. The 8-week treatment period is relatively short for assessing chronic diabetes management. The study does not report on potential drug interactions or adverse effects. Sample sizes per group (~9-10 rats) are small.
Questions This Raises
- ?Would the triple combination of exenatide, empagliflozin, and quercetin show the same synergistic benefits in human clinical trials?
- ?Could quercetin supplementation meaningfully enhance outcomes for patients already on GLP-1 agonist and SGLT2 inhibitor therapy?
- ?How do the long-term safety profiles of these three drugs interact when used in combination?
Trust & Context
- Key Stat:
- Triple combo uniquely reduced insulin resistance Only the combination of exenatide + empagliflozin + quercetin significantly decreased HOMA-IR and leptin levels, effects that no single drug achieved alone
- Evidence Grade:
- This study is graded as preliminary because it was conducted in rats with chemically induced diabetes. While the comparison design is informative, no human data supports these specific combination findings yet.
- Study Age:
- Published in 2024, this is a recent study relevant to current combination therapy strategies for type 2 diabetes.
- Original Title:
- The comparison of the antidiabetic effects of exenatide, empagliflozin, quercetin, and combination of the drugs in type 2 diabetic rats.
- Published In:
- Fundamental & clinical pharmacology, 38(3), 511-522 (2024)
- Authors:
- Korkmaz, Yasemin, Dik, Burak(2)
- Database ID:
- RPEP-08586
Evidence Hierarchy
Frequently Asked Questions
What is exenatide and how is it different from semaglutide?
Exenatide (sold as Byetta and Bydureon) is a GLP-1 receptor agonist — the same drug class as semaglutide (Ozempic/Wegovy). Originally derived from Gila monster venom, exenatide was the first GLP-1 drug approved. It's given by injection and works by stimulating insulin release, slowing digestion, and reducing appetite. Semaglutide is a newer, more potent GLP-1 drug given less frequently, but both target the same receptor.
Can I add quercetin to my diabetes medication?
While this rat study suggests quercetin may complement diabetes drugs, it's important not to change your treatment based on animal research. Quercetin is a common dietary supplement, but its effects in combination with prescription diabetes medications have not been proven in human clinical trials. Always consult your doctor before adding supplements to a diabetes treatment plan.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-08586APA
Korkmaz, Yasemin; Dik, Burak. (2024). The comparison of the antidiabetic effects of exenatide, empagliflozin, quercetin, and combination of the drugs in type 2 diabetic rats.. Fundamental & clinical pharmacology, 38(3), 511-522. https://doi.org/10.1111/fcp.12975
MLA
Korkmaz, Yasemin, et al. "The comparison of the antidiabetic effects of exenatide, empagliflozin, quercetin, and combination of the drugs in type 2 diabetic rats.." Fundamental & clinical pharmacology, 2024. https://doi.org/10.1111/fcp.12975
RethinkPeptides
RethinkPeptides Research Database. "The comparison of the antidiabetic effects of exenatide, emp..." RPEP-08586. Retrieved from https://rethinkpeptides.com/research/korkmaz-2024-the-comparison-of-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.